Project Manager

Peter Stephen Haddock, PhD.

** ******** ** • Milford, CT 06460

Mobile: 860-***-**** • Email: ************@***.***

http://www.linkedin.com/pub/peter haddock/23/545/b1

An experienced and self-motivated cardiovascular pharmacologist with 10 years post-doctoral

training and 15 years of pharma-based cardiovascular and neuroscience-focused drug

discovery project leadership. A collaborative, results-orientated leader and drug hunter with

effective influencing, problem-solving and communication skills. A scientific and technical

expert with an ability to operate effectively in situations of ambiguity, and to work productively in

a team environment.

Scientific, drug discovery & leadership skills

• Managed pre-clinical cardiovascular and neuroscience drug discovery projects from

target identification through to candidate nomination

• Established and led core safety pharmacology groups within major pharma organizations

• Scientific impact on global and cross-functional teams, external collaborations and in-

licensing initiatives

• Recognized scientific and technical expert in CV physiology, safety pharmacology and drug

discovery

• Executed and delivered innovative solutions as part of continual improvement initiatives

• Developed, communicated and implemented strategic vision regarding new targets and

technologies. Acted as a local and global scientific resource regarding target validation,

prosecution, new screening technologies and disease area focus.

• Served on matrix-style teams throughout a pre-clinical candidates lifecycle

• Effective communication to executive management and scientific colleagues at

national and international scientific and corporate meetings to introduce new targets,

technologies and strategic vision

• Lobbied for and drove the successful implementation of new technologies within two

pharma organizations

Professional Experience

Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT (2009-2012)

Senior Research Fellow – Compound Profiling Group

• Lead a cross function cardiovascular lab group focused on delivering screening data to

drive target and safety-based SAR

• Developed and implemented an internal strategy for integrated cardiovascular efficacy

and safety assessment

• Scientific expert on CV-related projects and safety representative on project and in-

licensing teams

• Member of leadership team

• Member of new target groups in CVMED, chronic kidney disease and inflammation

• Introduced the use of stem cell-derived cardiomyocytes for CV target and safety

pharmacology assessment

Pfizer PGRD, Groton, CT (2007 – 2009)

Associate Research Fellow – CV/Neuroscience Biology

• Lead a pharmacology laboratory focused on psychotherapeutic and cardiovascular

projects

• Leadership of CV and neuroscience projects

• Provided scientific input and impact across multiple therapeutic areas and advocacy for

continual improvement through the identification and implementation of new technologies

• Scientific interface between pre-clinical and clinical development

• Member of CV and neuroscience new target focus groups

• Leadership of CV safety group (in vitro and in vivo)

• Provided leadership in interfacing with external vendors and academic collaborators to

shape and drive key strategic alliances from conception to completion

Pfizer PGRD, Ann Arbor, MI (2003–2007)

Associate Research Fellow – CV/CNS Biology lab leader

• Leadership of an ion channel pharmacology group, supporting projects across

multiple Discovery therapeutic areas, both locally and globally. Activities focused the

identification and implementation of novel high throughput ion channel screening

technologies to support local and global drug discovery programs

• Implemented the use of automated high-throughput electrophysiology screening

platforms for voltage-gated and ligand-gated ion channel drug discover

• Designed, validation and implemented high throughput cardiovascular ion channel

safety screens (e.g. hERG, Nav1.5, KvLTQ1/minK)

• Project leader for Cav-related hypertension project

• Global in vitro/in vivo scientific expert

• Biology lead for Nav channel project

• Provided scientific leadership to direct and indirect reports both at the bench and in

relevant meetings.

• Communicated and published data both as internal research reports and in peer-

reviewed scientific journals

Pfizer PGRD, Sandwich, United Kingdom (1999–2003)

Cardiovascular Pharmacology Team Leader

• Leadership and development of 5 in vitro and 7 in vivo biologists within the

cardiovascular therapeutic area

• Hypertension, atrial arrhythmia and thrombosis project team leader delivering

timely decisions and pre-clinical candidate molecules

• Drove in vitro and in vivo model development, study design, analysis, critique

and communication of data;

• Provided expert opinion at Manager and Director level in addition to clear and

timely decision making.

NYU Medical Centre, New York City, USA (1995–1999)

Assistant Professor Pediatric Cardiology

• Led Grant-funded studies to investigate the regulation of intracellular Ca during

postnatal development.

• Undertook a large component of laboratory work (patch clamp electrophysiology in

native cardiac myocytes and transfected cell lines in addition to confocal assessment of

intracellular calcium flux

• Wrote project grants for external funding and communicated of data at external

scientific meetings

• Provided graduate teaching and scientific mentorship

Cardiovascular Research, The Rayne Institute, St. Thomas’ Hospital, London (1991 –

1995)

Wellcome Trust post-doctoral research Fellow

• Postdoctoral fellow focused on the investigation of the regulation of intracellular

calcium and ion channel function in the ischemic heart

Education

PhD. Cardiovascular Pharmacology, University of Bath, Bath, United Kingdom (1991)

BSc. (Hons.) Applied Biochemistry, Brunel University, London, United Kingdom (1988)

Book chapters

1. Haddock, P.S and Shattock, M.J. Oxidant stress and the heart: Modulation of ion

transport mechanisms during ischaemia and reperfusion. In: Immunopharmacology of free

radical species, edited by Blake, D. and Winyard, P.London:Academic Press p. 54-72, 1995

2. Haddock, P.S., Coetzee, W.A., Nakamura, T., Balaguru, D., and Artman, M Perinatal

maturation of myocardial contraction: The role of Na Ca exchange The Developing Heart,

edited by Ostadal,B.,Nagano,M., Takeda,.N., Dhalla, N.S.New York:Lippencott-Raven, p. 231-

245, 1997

Academic research publications in peer-reviewed journals

1. Falconer M., Smith F., Surah-Narwal S., Congrave G., Liu Z., Hayter P., Ciaramella G.,

Keighley W., Haddock P., Waldron G., and Sewing A. High-throughput screening for ion

channel modulators. J. Biomolecular Screening 7: 460-466, 2002.

2. WalkerJ,HughesB, James I, Haddock P, Kluft C, Bajzar L. Stabilization versus

inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem. 278(11): 8913-8921,

2003.

3. MacInnes A., Fairman D.A., Binding P., Rhodes J., Wyatt MJ., Phelan A., Haddock PS.,

Karran EH. The Anti-Anginal Agent Trimetazidine Does Not Exert Its Functional Benefit

Via Inhibition Of Mitochondrial Long Chain 3-KetoAcyl CoA Thiolase. Circ Res 8;93(3):

e26-32, 2003

4. Haddock P. Is this the golden age of ion channel research? High-throughput

electrophysiology platforms as enablers: American Pharmaceutical Review 9(1): 119-

122, 2006

5. Haddock P. Ion Channel Drug Discovery – Acceleration Through Innovation:

European Pharmaceutical review January 2007

6. Haddock P. Four Pillars of Modern Day Ion Channel Drug Discovery. Drug Discovery

Today (February 2009)

7. Haddock P. Optimizing Ion Channel Drug Discovery for Neurological Disorders: From

Idea to Proof of Concept. European Pharmaceutical Review (February 2009)

8. Haddock, P.S. and Hearse, D.J. Ventricular glutathione content and Na-K ATPase

activity. Biochem.Soc.Trans. 21:86S, 1993.

9. Galinanes, M., Smolenski, R.T., Haddock,P.S ., and Hearse, D.J. Early effects of

hypothyroidism on the contractile function of the rat heart and its tolerance to

hypothermic ischemia. J.Thorac.Cardiovasc.Surg. 107:829-837, 1994.

10. Haddock, P.S., Woodward, B., and Hearse, D.J. Cardiac Na-K ATPase activity and its

relation to myocardial glutathione status: Studies in the rat. J.Mol.Cell Cardiol. 27:1185-

1194, 1995.

11. Haddock, P.S. and Hearse, DJ. Sensitivity of cardiac Na-K pump current to oxidant

stress: Role of protein sulfhydryl and non-protein sulfhydryl redox status. Am.J.Physiol.

269:H297 H307,1995.

12. Thomas, J.A., Zhao, W., Hendrich, S. and Haddock,P.S . Analysis of cells and tissues

for S-thiolation of specific proteins. Methods in Enzymology. 251:423-429, 1995.

13. Haddock,P.S. Evidence for sodium dependent hypoxanthine uptake in isolated guinea

pig ventricular myocytes: stimulation by extracellular Ni Cardiovasc.Res:130137,1995

14. Connaughton M.,.F.J.,Haddock P.S., Hearse D.J. and Shattock M.J. Ventricular arrhythmias

induced by ischaemia-reperfusion are unaffected by myocardial glutathione depletion.

J.Mol.Cell Cardiol. 28(4):679-88, 1996

15. Qiu Y., Galinanes M., Haddock P.S. and Hearse D.J. Continuous warm versus

intermittent cold cardioplegic infusion: a comparison of energy metabolism, sodium-

potassium adenosine triphosphatase activity, and postischemic functional recovery in

the blood-perfused rat heart. J.Thorac.Cardiovasc.Surg. 112(3): 797-805, 1996.

16. Avkiran, M., Ibuki, C., Shimada, Y., and Haddock, P.S. Effects of acidic reperfusion on

arrhythmias and Na-K ATPase activity in regionally ischemic rat hearts. Am.J.Physiol.

270:H957 64,1996.

17. Haddock, P.S., Coetzee, W.A., and Artman, M. Charge movement via Na-Ca exchange

current measured under chloride-free conditions in developing rabbit ventricular

myocytes. Am. J. Physiol. 273: H837-H846, 1997.

18. Balaguru, D., Haddock, P.S., Puglisi, J.L., Bers, D., Coetzee, W.A. and Artman,

M. Role of the sarcoplasmic reticulum in contraction and relaxation of immature

rabbit ventricular myocytes. J. Mol. Cell. Cardiol. 29: 2747-2757, 1997

19. Haddock PS, Artman M, Coetzee WA. Influence of postnatal changes in action

potential duration on Na-Ca exchange in rabbit ventricular myocytes. Pflugers Arch.

1998 May;435(6):789-9

20. Haddock,.P.S.,Cho, E., Coetzee, W.A., Bers,D.M. AND M. Artman. Subcellular [Ca ]i

gradients during excitation-contraction coupling in newborn rabbit ventricular myocytes.

Circ. Res. 85(5): 415-427, 1999.

Invited oral presentations at external scientific meetings

1. “High throughput ion channel screening”: Pharma Discovery, Washington DC,

May 2005

2. “Integrating High Throughput Electrophysiology into the Drug Discovery

Process”: Molecular Devices Automated Electrophysiology Users Meeting, Salt Lake

City, February 2006

3. “Development of Ion Channel Targeted Therapies Using Emerging High

Throughput Electrophysiology Platforms”: Discovery on Target, Boston, October 2006

4. “Ion Channel Drug Discovery – Acceleration through Innovation” : Molecular Devices

Automated Electrophysiology Users Meeting, Baltimore, 2007

5. Aurora Biomed's 5th Annual Ion Channel Retreat, June 25-27th, 2007 in

Vancouver, Canada.

6. “Ion Channels as Therapeutic Targets: An Industry Minireview” Discovery on Target,

Boston, October 2008

Research abstracts

1. Haddock, P.S., Hearse, D.J., and Woodward, B. Effect of antioxidants and verapamil on

noradrenaline release and contracture in the ischaemic/reperfused rat heart.

Br.J.Pharmacol. 78:745-745, 1989.

2. Haddock, P.S., Hearse, D.J., and Woodward, B. Effect of glutathione and other thiols

on bovine heart Na-K ATPase activity. J.Mol.CellCardiol. 22:S.4, 1990.

3. Haddock, P.S., Woodward, B., Hearse, D.J., and Dodds, R. Modification of the activity

of bovine Na-K ATPase by reduced and oxidised glutathione and other sulphydryl compounds.

Br.J.Pharmacol. 102:54P, 1991.

4. Haddock, P.S. and Shattock, M.J. Chemical oxidation of sulphydryl groups

results in a depression of Na-K pump current in isolated adult guinea pig ventricular myocytes.

J.Physiol-London.473:182P 182P,1993.

5. Shattock, M.J., Matsuura, H., Haddock, P.S., and Hearse, D.J. Effects of oxidant stress

on membrane currents in isolated cardiac myocytes. J.Mol.Cell Cardiol. 25:L2-L2, 1993.

6. Shattock, M.J., Hatrick, R.I., Miller, J.I.A., and Haddock, P.S. Intracellular glutathione

level influences SR calcium loss during rest in cardiac muscle.

J.Mol.Cell Cardiol.26:534 534,1994.

7. Haddock, P.S., Shattock, M.J., and Hearse, D.J. Reversible protein sulphydryl

oxidation modulates cardiac Na-K pump current. J.Mol.Cell Cardiol. 26:253 253,1994.

8. Avkiran, M., Haddock, P.S., and Ibuki, C. Antifibrillatory effect of transient acidic

reperfusion: Role of Na-K ATPase activity. J.Mol.Cell Cardiol.26:445 445,1994.

9. Haddock, P.S. Inhibition of Na-K pump current by ATP catabolites in adult

isolated guinea pig ventricular myocytes. J.Physiol.Lond.477:15P 15P,1994.

10. Haddock, P.S., Coetzee, W.A., and Artman, M. Ontogeny of forward and reverse-mode

Na-Ca exchange in the developing rabbit heart. Circulation 94:I-118-I-118, 1996.

11. Balaguru, D., Haddock, P.S., Coetzee, W.A., and Artman, M. Cardiac sarcoplasmic

reticulum in neonates can release calcium comparable to adult myocytes. Circulation

94:I-482-I-482, 1996.

12. Haddock, P.S., Artman, M. and Coetzee, W.A. Na-Ca exchange inhibitory peptide

prevents apparent depolarization-induced calcium release in rat ventricular myocytes.

Circulation 96:I-991, 1997.

13. Haddock, P.S., Artman, M., and Coetzee, W.A. Action potential voltage clamp of Na-Ca

exchange current: age-dependent changes in rabbit ventricle. Biophys.J. 72:A67-A67, 1997.

14. Cho, E., Haddock, P.S., Coetzee, W.A. and Artman, M. Spatial and temporal changes

in [Ca]i in developing rabbit ventricular myocytes. Biophys.J. 74: A267 1998.

15. Haddock, P.S., Artman, M. and Coetzee, W.A. Is the Na-Ca exchanger involved in

apparent depolarization-induced calcium release in cardiac myocytes? Biophys.J: A271 1998.

16. Haddock, P.S. T-tubule biogenesis in developing rabbit myocytes. (American Heart

Association Scientific Sessions, 1998).

17. Haddock, P.S.,Coetzee,W.A and Artman,M. Contribution of SR Ca stores to

developmental differences in subcellular Ca gradients in rabbit myocytes. (American Heart

Association Scientific Sessions, 1998).

References available on request

Contact this candidate